The Diagnostic Snapshot Problem
When a patient comes in for a cardiology visit, the first thing you get is a 12-lead ECG. It captures 10 seconds of rhythm. In most cases, that 10-second strip is clean sinus rhythm because the patient is sitting still in a climate-controlled clinic, mildly anxious, and not in a paroxysmal arrhythmia episode at the exact moment the recording starts. A healthy 10-second ECG is not a negative arrhythmia workup. It is evidence of what the heart was doing for those 10 seconds, nothing more.
The mismatch between what the in-office ECG captures and what actually drives clinical risk for many patients is one of the oldest problems in outpatient cardiology. The profession has known this since Holter monitoring was introduced in the 1960s. The issue has not been the diagnostic insight. It has been the operational bottleneck between the patch data coming in and a cardiologist seeing it.
When the monitoring period ends and the patient uploads their patch data, that data sits somewhere pending analysis. If analysis runs automatically but produces a report that goes into an inbox without priority routing, the cardiologist sees it when they get to it. For a practice managing 40 to 80 active monitoring patients at any given time, "when they get to it" can mean two to five days. For a paroxysmal AFib episode detected on day 10 of a 14-day patch, the intervention window may have already opened and partially closed before the finding reaches clinical review.
What Ambulatory Monitoring Finds That Clinic Visits Miss
The clinical literature on ambulatory ECG monitoring contains a consistent finding: detection rates for clinically significant arrhythmias are substantially higher with extended monitoring than with resting ECGs or standard 24-hour Holter recordings. This is not a surprising result. It follows directly from the mathematics of episode prevalence and recording window.
Paroxysmal AFib is the canonical example. In patients referred for palpitation evaluation or post-stroke rhythm assessment, 30-day extended monitoring detects AFib in a meaningfully higher proportion of patients compared to 24-hour Holter or repeated resting ECGs. The mechanism is simple: the episodes are brief and infrequent. A 24-hour window misses most of them. A 14 to 30-day window with continuous monitoring captures the rhythm over a period long enough to include event days for most patients with any meaningful AF burden.
Symptomatic bradycardia presents the same pattern. A patient whose average resting rate is 58 bpm in clinic and who reports dizziness three or four times per week may have isolated sinus pauses during those episodes that are only visible during real-world activity. The in-office ECG is clean. The ambulatory recording captures the pause during the actual symptomatic event.
Non-sustained ventricular tachycardia (NSVT) is another rhythm category that is almost exclusively detected through ambulatory monitoring in outpatients. NSVT may be clinically significant in structural heart disease (post-myocardial infarction, hypertrophic cardiomyopathy, cardiac sarcoidosis) and essentially invisible on a resting ECG unless the patient happens to have an episode during the 10-second recording window. This is vanishingly rare.
The Review Gap: When Data Exists but Does Not Reach Clinical Action
The monitoring gap is not always about missing data. Sometimes the data exists and the clinical response is still delayed. This is the review gap, and it is the part of the problem that technology can address most directly.
In cardiology practices that run patch monitoring programs without automated alert routing, the typical workflow is: patch data is uploaded and analyzed, a PDF report is generated, the report is delivered to a clinic inbox or fax, a staff member routes it to the ordering cardiologist, the cardiologist reviews it at their next available window. At each handoff step, time passes. For routine or negative reports, that delay is not clinically consequential. For a high-priority finding, it can be.
The monitoring gap becomes clinically significant in the interval between a detected arrhythmia event and the clinical decision that follows from it. For a new paroxysmal AFib detection in a patient not currently anticoagulated, that decision involves assessing stroke risk (CHA2DS2-VASc), discussing anticoagulation options, and potentially expediting follow-up. Each day of delay in that decision is a day of theoretical stroke risk that could have been addressed.
This is the problem ElectroKare is designed to solve. When the AI analysis identifies a priority-tier arrhythmia, the alert goes to the cardiologist immediately, not through a PDF inbox chain. The cardiologist receives the finding with an ECG strip excerpt and relevant patient context before the next batch review cycle. In our pilot practices, the median time from patch upload to alert was 38 seconds. What happens clinically after the alert is the cardiologist's decision. Our job is to make sure the right person sees the right finding at the right time.
What Does Not Get Detected: An Honest Boundary
Ambulatory ECG patches are valuable for rhythm monitoring. They are not designed to detect structural or hemodynamic changes that do not manifest as rhythm disturbances in the ECG signal.
Worsening left ventricular function, rising filling pressures in heart failure, new coronary artery disease in a patient without ischemia-driven arrhythmia, blood pressure changes: none of these are captured by ambulatory ECG monitoring. A practice that installs a 14-day patch program and expects it to reduce readmissions across their general cardiology population will be disappointed. A practice that targets specific patients where rhythm detection drives specific clinical decisions will see a different result.
We think it is important to say this clearly because the monitoring technology space benefits when the clinical case is made accurately. Overselling ambulatory ECG as a comprehensive post-discharge surveillance tool invites appropriate skepticism and makes it harder to make the genuine case for the populations where it adds unambiguous value.
The Data Staleness Problem Is Underappreciated
There is a secondary version of the monitoring gap that most practices do not explicitly plan for: data staleness. A 14-day patch recording that is reviewed 10 days after the monitoring period ends is, by definition, looking at cardiac data from up to 24 days ago. The patient's clinical status may have changed. They may have already seen their primary care physician. They may have had a symptomatic episode and visited an urgent care clinic in the interval.
When the cardiologist finally reviews a monitoring report and finds a previously undetected AFib episode, the clinical response should account for the elapsed time since the event. Starting anticoagulation based on a paroxysmal AFib episode detected 12 days ago is a different clinical context than acting on a finding from two days ago. The review delay does not change the fact that the finding is clinically relevant, but it changes the framing of the conversation with the patient and potentially the urgency of the response.
Monitoring programs designed around immediate alert routing do not eliminate this problem entirely, but they compress the interval substantially. The goal is to surface the finding while it is still recent enough that the clinical response is timely rather than retrospective. A cardiologist reviewing a priority AFib alert the same day it was detected is in a qualitatively different clinical position than one reviewing a two-week-old monitoring report on a patient they are seeing today for a scheduled visit.
Structuring a Practice to Benefit from What Monitoring Can Tell You
The practices that extract the most clinical value from ambulatory monitoring programs are not necessarily the ones with the most sophisticated technology. They are the ones with an explicit protocol for what happens after an alert arrives.
The questions worth answering before a program goes live: Which patients are in the monitoring program, and what are the specific clinical decisions that will be made based on the findings? When a priority alert arrives, who reviews it and within what time window? When the reviewing cardiologist decides on a clinical response, how is that documented and communicated to the patient?
The monitoring program answers the rhythm question. The clinical protocol answers what happens next. Both need to be designed deliberately. The gap between a monitored patient and a better outcome is filled by both halves working together. Ambulatory monitoring closes the diagnostic window between visits. A structured response protocol converts what monitoring finds into clinical action before the window closes again.